Refine by
Hematopoietic Stem Suppliers & Manufacturers
31 companies found
Premium
based inDueren, GERMANY
Since 2005, NIPPON Genetics EUROPE has stood for innovation and quality in biotechnology. In these two decades, we have evolved from a supplier of high quality Japanese technologies to a developer of our own groundbreaking solutions. Our products ...
Enables long term cell storage at -80°C or -196°C. Improved cell recovery and viability after thawing. Ready-to-use freezing media – no programmed or sequential freezing required. Serum-free – no risk of contamination. GMP ...
based inAllendale, NEW JERSEY (USA)
We are a leading global contract development and manufacturing organization (CDMO) dedicated to the advancement and manufacturing of gene and cell therapy products. Minaris Regenerative Medicine is a leading global contract development and ...
At Minaris Regenerative Medicine, we are committed to bringing together and further developing highly talented, skilled, and dedicated experts with varied backgrounds applicable to gene and cell therapy manufacturing and development. Having this ...
based inBeachwood, OHIO (USA)
We develop cell therapies - at a dramatically increased speed, at lower cost, and with less R&D risk. Trailhead Biosystems merges developmental biology and cell therapeutics with cutting-edge hardware and computerized experimental design and ...
We are developing human long-term hematopoietic stem cells (LT-HSCs) from human (non-embryo) induced pluripotent stem cells (iPSCs). HSCs are rare subsets of hematopoietic cells ...
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
MPC-25-IC is Mesoblast’s Phase 2 product candidate for the treatment of acute myocardial infarction. This is the first clinical study to evaluate an allogeneic cellular therapy delivered by intracoronary infusion in patients who have suffered ...
based inSan Antonio, TEXAS (USA)
StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of ...
CELLvo™ Matrix is the only commercially available substrate that aims to recapitulate biochemical as well as structural and mechanical cues of the native niche by leaving the extracellular matrix intact. Cell-derived matrices create a ...
based inParis, FRANCE
We are a biotech company combining microfluidics, digitalization and bioengineering to make high quality biological therapies at affordable cost and minimized environmental impact. Therapeutic cells can multiply in the patient's body. This allows ...
Hematopoietic stem cells (HSCs) are mothers to all blood cells including erythrocytes and lymphocytes. We develop high quality genetically edited HSCs to cure an undisclosed hereditary blood disease. This ...
based inAlameda, CALIFORNIA (USA)
Since its inception in 1998, AllCells, a Discovery Life Sciences Company, has focused on advancing science in an innovative, collaborative, and client-centric manner. In our corporate video, AllCells’ Founder, Jay Tong, describes his early days in ...
Mobilized Leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate the migration of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow niche ...
based inGrove City, OHIO (USA)
Forge is developing innovative gene therapies that aim to help patients suffering from devastating rare diseases. Forge is building capacity to directly address the growing demand for gene therapy manufacturing. Forge is currently building the ...
Krabbe disease is a devastating neurodegenerative disease affecting about 1 -2.5 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase ...
based inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using our novel eHSC platform. Our research demonstrates that multiplex genome editing of allogeneic hematopoietic ...
based inNoida, INDIA
Advancells is a research-oriented company, focussed on offering authentic, high-quality primary cells including stem cells for research studies, stem cell therapy, preclinical analysis, and even as in vitro tools for clinical research. We wish to be ...
Stroke is mainly characterized by a decreased supply of oxygenated blood to two primary organs of the body, either heart or brain, especially due to blocked and/or ruptured arteries. Specifically, there are three type of Stroke: (a) Ischemic stroke ...
based inTokyo, JAPAN
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the ...
Somatic stem cell regenerative medicine utilizes somatic stem cells, which are present in various tissues of the body, with the aim of developing new treatments for diseases for which the current standard of care may be limited or unavailable to ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
TZ 102, like all of TargaZyme’s therapeutics, is an off-the-shelf product for point-of-care use. It’s made of two (2) components, fucosyltransferase VII enzyme and GDP ...
based inMountain View, CALIFORNIA (USA)
Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to ...
CBM588 is an orally-administered Clostridium butyricum strain with a long history of clinical use and safety in all age groups in Japan. In Japan, CBM588 has primarily been used to treat infectious and noninfectious diarrheal disorders associated ...
based inChangning District, CHINA
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative ...
Diffuse large B-cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin lymphoma (NHL) in adults and a highly heterogeneous malignancy in both clinical manifestations and prognosis. DLBCL accounts for 30%-40% of all NHL cases, and over ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inSeattle, WASHINGTON (USA)
We believe we are entering a new era of medicine. The ability to modify genes and use cells as medicines provides new tools to meaningfully change the outcome of many human diseases. Early pioneers have made good progress, but most of what we can ...
Hemoglobinopathies: Sickle cell disease, ...
based inMilano, ITALY
We are a clinical-stage biotechnology company pioneering the treatment of cancers with a technology platform that allows the direct delivery of immunotherapeutic payloads within the tumor microenvironment. Intrinsic resistance significantly reduces ...
Temferon™ is a lenti-virus based hematopoietic stem progenitor cell immuno-gene therapy enabling controlled and targeted interferon-α expression within cancers. Biologically delivered via engineered ...
based inCambridge, MASSACHUSETTS (USA)
Editas Medicine is a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around ...
EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). EDIT-301 consists of patient-derived CD34+ hematopoietic ...
based inVancouver, BRITISH COLUMBIA (CANADA)
STEMCELL Technologies provides high-quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources to scientists around the world working on stem cell, immunology, cancer, regenerative medicine, ...
Basic fibroblast growth factor (bFGF) is a prototypic member of the fibroblast growth factor family. Cytokines in the FGF family possess broad mitogenic and cell survival activities (Folkman & Klagsbrun; Kimelman & Kirschner) and are ...